Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 338-343

  Colella, G ^a   Marchini, S ^a   D'Incalci, M ^a   Brown, R ^b   Broggini, M ^a  

^a Molecular Pharmacology Unit   (Italy)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Alkylating agents; Minor groove binders; Mismatch repair

Indexed keywords

ADENINE; ALKYLATING AGENT; CARZELESIN; CISPLATIN; DISTAMYCIN A DERIVATIVE; PNU 151807; RACHELMYCIN; TALLIMUSTINE; UNCLASSIFIED DRUG;

ARTICLE; BASE MISPAIRING; CELL LINE; CHEMICAL STRUCTURE; CHROMOSOME 3; COLON CARCINOMA; CYTOTOXICITY; DNA REPAIR; DRUG RESISTANCE; GENE MUTATION; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE PAIR MISMATCH; COLORECTAL NEOPLASMS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032956375     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690360     Document Type: Article

References (24)

1. Aebi S, Kurdi-Hadar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087-3090
2. Aebi S, Fink D, Gordon R, Ki Kim H, Zheng H, Fink JL and Howell SB (1997) Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3: 1763-1767
3. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR and Brown R (1996) Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374-1381
4. Branch P, Aquilina A, Bignami M and Karran P (1993) Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362: 652-654
5. Branch P, Hampson R and Karran P (1995) DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55: 2304-2309
6. Broggini M, Erba E, Ponti M, Ballinari D, Geroni C, Spreafico F and D'Incalci M (1991) Selective DNA interaction of the novel distamycin derivative FCE24517. Cancer Res 51: 199-204
7. Broggini M, Coley HM, Mongelli N, Pesenti E, Wyatt MD, Hartley JA and D'Incalci M (1995) DNA sequence-specific adenine alkylation by the novel antitumor drug tallumustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res 23: 81-87
8. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, Van Der Zee Age and Anthoney DA (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45-52
9. D'Alessio R, Geroni C, Biasoli G, Pesenti E, Grandi M and Mongelli N (1994) Structure-activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorganic Med Chem Lett 4: 1467-1472
10. D'Incalci M and Sessa C (1997) DNA minor groove binding ligands: a new class of anticancer agents. Exp Opin Invest Drugs 6: 875-884
11. Damia G, Iperatori L, Cilti L, Mariani L and D'Incalci M (1996a) 3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. Br J Cancer 73: 861-865
12. Damia G, Imperatori L, Stefanini M and D'Incalci M (1996b) Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anticancer agents. Int J Cancer 66: 779-783
13. Drummond JT, Anthoney DA, Brown R and Modrich P (1996) Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645-19648
14. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmè A, Christen RD and Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886
15. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehmè A, Christen RD, Haas M, Macleod CL and Howell SB (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57: 1841-1845
16. Fishel R and Kolodner RD (1995) Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5: 382-395
17. Ghielmini M, Bosshard G, Capolongo L, Geroni MC, Pesenti E, Torri V, D'Incalci M, Cavalli F and Sessa C (1997) Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 75: 878-883
18. Hurley LH, Reynolds VL, Swenson DH, Petzold GL and Scahill TA (1984) Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science 226: 843-844
19. Karran P and Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833-839
20. Karran P and Hampson R (1996) Genomie instability and tolerance to alkylating agents. Cancer Surv 28: 69-85
21. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA and Boland CR (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312
22. Li LH, Dekoning TF, Kelly RC, Krueger WC, McGovren JP, Padbury GE, Petzold GL, Wallace TL, Ouding RJ, Prairie MD and Gebhard I (1992) Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res 52: 4904-4913
23. Marchini S, Cozzi P, Beria I, Geroni C, Capolongo L, D'Incalci M and Broggini M (1998) Sequence specific alkylation of novel tallimustine derivatives. AntiCancer Drug Design 13: 193-205
24. Martin DG, Biles C, Gerpheide SA, Hanka LJ, Krueger WC, McGovren JP, Mizsak SA, Neil GL, Stewart JC and Visser J (1981) CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot Tokyo 34: 1119-1125